HUTCHMED (China) Limited (HCM)
| Market Cap | 6.98B |
| Revenue (ttm) | 257.96M |
| Net Income (ttm) | n/a |
| Shares Out | 172.82M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $39.42 |
| Previous Close | $40.39 |
| Change ($) | -0.98 |
| Change (%) | -2.41% |
| Day's Open | 39.22 |
| Day's Range | 38.70 - 39.60 |
| Day's Volume | 54,259 |
| 52-Week Range | 23.67 - 43.36 |
The European Medicines Agency (EMA) has validated and accepted Hutchmed (China) Limited's (NASDAQ: HCM) marketing application seeking approval for surufatinib for pancreatic and extra-pancreatic (non-pa...
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –
As of late, it has definitely been a great time to be an investor of HUTCHMED (China) Limited (HCM).
Hutchison China MediTech (HCM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made i...
Hutchmed (China) Limited (NASDAQ: HCM) announces the first commercial sale in China of Orpathys (savolitinib), a selective small-molecule inhibitor of MET, a receptor tyrosine kinase. It follows less th...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of th...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., July 05, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL-295, its investigati...
HONG KONG and SHANGHAI, China and & FLORHAM PARK, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the ...
– U.S. FDA has assigned a target action date of April 30, 2022 –
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordi...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its glob...
– First selective MET inhibitor approval in China in this setting –
– Second New Drug Application (“NDA”) approved for Sulanda in China –
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Ko...
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and pr...
– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones – – HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to pro...
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, furthe...
First NDA submission by HUTCHMED in the U.S.; product launch preparations underway First NDA submission by HUTCHMED in the U.S.; product launch preparations underway
— Single-arm study in ~180 patients, with ORR as primary endpoint —
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Hutchison China MediTech (HCM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development — — HMPL-306 is the sixth innovative oncology drug candidate discovered in hou...
Hutchison China MediTech (NASDAQ: HCM) has agreed to sell its non-core and non-consolidated over-the-counter drug joint venture business to GL Capital Group. The sale of our shares in the joint venture,...
Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets Allows focus on China and global clinical development and market launches of key Oncology/Immu...
Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in comb...
Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year e...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Pha...
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) ...
– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China –
– Company plans to complete rolling submission in the first half of 2021 –
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executiv...
Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and support an...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first ...
― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“N...
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, it...
HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of sur...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it received scientific advice fro...
Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib –
HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administra...
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an am...
— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
LONDON, June 18, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Des...
About HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fru... [Read more...]
| Industry Biotechnology | |
| CEO Christian Hogg | Employees 1,280 |
| Stock Exchange NASDAQ | Ticker Symbol HCM |
Financial Performance
In 2020, HUTCHMED's revenue was $227.98 million, an increase of 11.27% compared to the previous year's $204.89 million. Losses were -$125.73 million, 18.6% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for HUTCHMED stock is "Strong Buy." The 12-month stock price forecast is 41.40, which is an increase of 5.04% from the latest price.